Impurities of tazarotene : Isolation and structural characterisationBRENNA, Elisabetta; FRIGOLI, Samuele; FRONZA, Giovanni et al.Journal of pharmaceutical and biomedical analysis. 2008, Vol 46, Num 3, pp 574-576, issn 0731-7085, 3 p.Article

Cumulative Irritation Potential and Contact Sensitization Potential of Tazarotene Foam 0.1% in 2 Phase 1 Patch StudiesBERG, Jeffrey E; BOWMAN, James P; ALIO SAENZ, Alessandra B et al.Cutis (New York, NY). 2012, Vol 90, Num 4, pp 206-211, issn 0011-4162, 6 p.Article

Le médicament du mois : Tazarotène 0,05 %-0,1 % (Zorac®) = Tazarotene 0.05 %-1.1 % (Zorac®)HENNO, A; HUA, M.-T; DE LA BRASSINNE, M et al.RMLG. Revue médicale de Liège. 2003, Vol 58, Num 11, pp 706-708, issn 0370-629X, 3 p.Article

Tazarotene: A New Generation of Receptor-Selective Retinoids. SymposiumJournal of the American Academy of Dermatology. 1997, Vol 37, Num 2, issn 0190-9622, 42 p., 3Conference Proceedings

Pharmacokinetics and safety review of tazarotene. DiscussionMARKS, R; HORN; YOUNG et al.Journal of the American Academy of Dermatology. 1998, Vol 39, Num 4, pp S134-S138, issn 0190-9622, 2Conference Paper

Optimising the use of tazarotene in clinical practice : Consensus statement from the European Advisory Panel for tazarotene (Zorac⁾GOLLNICK, H. P. M; FINZI, A. F; MARKS, R et al.Dermatology (Basel). 1999, Vol 199, Num 1, pp 40-46, issn 1018-8665Conference Paper

Effects of tazarotene 0.1% cream in the treatment of facial acne vulgaris: Pooled results from Two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trialsSHALITA, Alan R; BERSON, Diane S; THIBOUTOT, Diane M et al.Clinical therapeutics. 2004, Vol 26, Num 11, pp 1865-1873, issn 0149-2918, 9 p.Article

A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophyKAIDBEY, Kays; KOPPER, Scott C; SEFTON, John et al.International journal of dermatology. 2001, Vol 40, Num 7, pp 468-471, issn 0011-9059Article

Phototoxic and Photoallergic Potential of Tazarotene Foam 0.1% in 2 Phase 1 Patch StudiesHOGAN, Daniel J; ALIO SAENZ, Alessandra B.Cutis (New York, NY). 2012, Vol 90, Num 5, pp 266-271, issn 0011-4162, 6 p.Article

Psoriasis ungueal: tratamiento con ungüento hidrófilo de tazaroteno al 0,1% = Nail Psoriasis: Treatment With Tazarotene 0.1% Hydrophilic OintmentFISCHER-LEVANCINI, C; SANCHEZ-REGANA, M; LLAMBI, F et al.Actas dermo-sifiliográficas (Ed. impresa). 2012, Vol 103, Num 8, pp 725-728, issn 0001-7310, 4 p.Article

A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasisTZANEVA, S; SEEBER, A; HÖNIGSMANN, H et al.British journal of dermatology (1951). 2002, Vol 147, Num 4, pp 748-753, issn 0007-0963, 6 p.Article

Transglutaminase 1 and its regulator tazarotene―induced gene 3 localize to neuronal tau inclusions in tauopathiesWILHELMUS, Micha Mm; DE JAGER, Mieke; ROZEMULLER, Annemieke Jm et al.Journal of pathology (Print). 2012, Vol 226, Num 1, pp 132-142, issn 0022-3417, 11 p.Article

Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasisKAUR, Inderjeet; DOGRA, Sunil; JAIN, Rajesh et al.Indian journal of dermatology venereology and leprology. 2008, Vol 74, Num 5, pp 471-474, issn 0378-6323, 4 p.Article

Downregulation of tazarotene induced gene-2 (TIG2) in skin squamous cell carcinomaZHENG, Yan; LUO, Suju; WANG, Guorong et al.EJD. European journal of dermatology. 2008, Vol 18, Num 6, pp 638-641, issn 1167-1122, 4 p.Article

Adapalene 0.1% and benzoyl peroxide 2.5% as a fixed-dose combination gel is as well tolerated as the individual components alone in terms of cumulative irritancyLOESCHE, Christian; PERNIN, Colette; PONCET, Michel et al.EJD. European journal of dermatology. 2008, Vol 18, Num 5, pp 524-526, issn 1167-1122, 3 p.Article

Confluent and Reticulate Papillomatosis Treated With Minocycline and TazaroteneTSENG, Hui-Wen; TSENG, Hui-Hwa; WU, Chieh-Shan et al.Cutis (New York, NY). 2013, Vol 91, Num 4, pp 194-197, issn 0011-4162, 4 p.Article

Topical tazarotene vs. coal tar in stable plaque psoriasisKUMAR, U; KAUR, I; DOGRA, S et al.Clinical and experimental dermatology (Print). 2010, Vol 35, Num 5, pp 482-486, issn 0307-6938, 5 p.Article

Lamellar ichthyosis treated with tazarotene 0.1% gelKUNDU, Roopal V; GARG, Amit; WOROBEC, Sophie M et al.Journal of the American Academy of Dermatology. 2006, Vol 55, Num 5, issn 0190-9622, S94-S95, SUPArticle

Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasisLEBWOHL, M; AST, E; QUELL, J. M et al.Journal of the American Academy of Dermatology. 1998, Vol 38, Num 5, pp 705-711, issn 0190-9622, 1Article

Expression and Mutation Analysis of TIG1 (Tazarotene-Induced Gene 1) in Human Gastric CancerMIN SOO SON; KANG, Min-Ju; HO CHUL PARK et al.Oncology research. 2009, Vol 17, Num 11-12, pp 571-580, issn 0965-0407, 10 p.Article

Topical retinoids in inflammatory acne : A retrospective, investigator-blinded, vehicle-controlled, photographic assessmentLEYDEN, James J; SHALITA, Alan; THIBOUTOT, Diane et al.Clinical therapeutics. 2005, Vol 27, Num 2, pp 216-224, issn 0149-2918, 9 p.Article

Rational design of receptor-selective retinoids. DiscussionCHANDRARATNA, R. A. S; MARKS; MORAHAN et al.Journal of the American Academy of Dermatology. 1998, Vol 39, Num 4, pp S124-S128, issn 0190-9622, 2Conference Paper

Tolerability comparison of adapalene gel, 0.3% versus tazarotene cream, 0.05% in subjects with healthy skin : AcneDOSIK, Jonathan S; ARSONNAUD, Stephanie.Journal of drugs in dermatology. 2007, Vol 6, Num 6, pp 632-638, issn 1545-9616, 7 p.Article

Tazarotene: a new topical retinoid for plaque psoriasisMARKS, R.British journal of dermatology. Supplement. 1999, Vol 140, Num 54, issn 0366-077X, 30 p.Conference Proceedings

Psoriasis : une nouvelle stratégie thérapeutique. ReportageLes Nouvelles dermatologiques. 1999, Vol 18, Num 6, pp 402-405, issn 0752-5370Conference Proceedings